Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 11:35:12 2024-05-14 EDT			5-day change	1st Jan Change
1.56 ^GBX	-2.19%		-0.32%	-32.17%

04-25	EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	AN
04-25	Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hemogenyx Pharmaceuticals completes process qualification run

January 08, 2024 at 05:58 am

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

The London-based biopharmaceutical company focused on treatments for deadly blood diseases said it successfully completed its process qualification run for the manufacture of HEMO-CAR-T cells.

It added that the process qualification run is the only manufacturing run required for the submission of a complete response to the clinical hold of the investigational new drug application to the US Food & Drug Administration for HEMO-CAR-T.

Chief Executive Officer Vladislav Sandler said: "We are pleased that we have now completed the necessary PQ run. We are now working hard to resubmit the IND as expeditiously as possible to move forward with clinical trials of HEMO-CAR-T."

Hemogenyx shares fell 8.7% to 2.10 pence each on Monday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Latest news about Hemogenyx Pharmaceuticals Plc

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	04-25	AN
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	02-29	AN
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	02-29	MT
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	02-16	MT
Hemogenyx shares rise on potential for CBR to treat brain diseases	02-16	AN
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	02-16	CI
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	02-14	MT
Hemogenyx says CBR can be used intranasally to treat viral infections	02-14	AN
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	02-09	AN
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	02-09	MT
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	02-09	CI
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	02-02	MT
Hemogenyx hails US patent application progress	02-02	AN
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	02-02	CI
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	01-16	AN
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application	01-16	MT
Hemogenyx Pharmaceuticals completes process qualification run	01-08	AN
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold	01-08	MT
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells	01-08	CI
Upland Resources completes technical study at Sarawak	11-28	AN
Hemogenyx Platform Shows Potential for Blood Cancer Treatment; Shares Climb	11-27	MT
Hemogenyx shares up as says CBR platform a potential cancer treatment	11-27	AN
Hemogenyx Pharmaceuticals plc Announces CBR Expanded to Treatment of Cancer	11-27	CI
Hemogenyx Pharmaceuticals completes lentivirus re-manufacture	11-15	AN

Chart Hemogenyx Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEMOGENYX PHARMACEUTICALS PLC	-32.17%	26.34M
VERTEX PHARMACEUTICALS INCORPORATED	+5.33%	111B
REGENERON PHARMACEUTICALS, INC.	+12.11%	106B
BIONTECH SE	-12.56%	22.24B
ARGENX SE	-3.70%	21.25B
GENMAB A/S	-6.03%	18.97B
WUXI APPTEC CO., LTD.	-35.21%	18.52B
BEIGENE, LTD.	-10.86%	16.81B
NEUROCRINE BIOSCIENCES, INC.	+5.10%	13.94B
SAREPTA THERAPEUTICS, INC.	+37.57%	12.54B

Bio Therapeutic Drugs